Clinical Trial Update: Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety and efficacy of gecacitinib for chronic graft-versus-host disease in patients with at least two prior therapies…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Gecacitinib (Gecacitinib)

Snippet

Sponsor: Yujun DONG | Conditions: Chronic Graft Versus Host Disease | Phase 1, Phase 2 | Status: RECRUITING